Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment
Purpose: Current understanding of COVID-19 disease progression suggests a major role for the "cytokine storm" as an important contributor to COVID-19 mortality. To prevent an exaggerated immune response and improve COVID-19 patient endpoints, anti-inflammatory therapeutics have been propos...
Saved in:
Main Authors: | Yewon Park (Author), Joo Young Na (Author), Joo-Youn Cho (Author), Jaeseong Oh (Author), Su-jin Rhee (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease
by: Xuanyou Jin, et al.
Published: (2020) -
Effects of meal type on the bioavailability of vutiglabridin, a novel anti‐obesity agent, in healthy subjects
by: Heejae Won, et al.
Published: (2024) -
Pharmacokinetic evaluation of radiolabeled intraocular anti‐CLEC14a antibody in preclinical animal species and application in humans
by: Sohyun Park, et al.
Published: (2022) -
Cecal epidermoid cyst: a neonatal case with clinicopathological consideration
by: Joo-Young Na, et al.
Published: (2021) -
Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase
by: Jihyun Kang, et al.
Published: (2022)